Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00917683 · ClinicalTrials.gov registry record
Investigation of Neuroserpin as an Autism Candidate Gene
A clinical trial, sponsored by State University of New York - Upstate Medical University.
- Terminated
- Registry status
- 5
- Enrollment target
NCT00917683 is a clinical trial that was terminated before completion, run by State University of New York - Upstate Medical University. The registered enrollment target is 5 participants.
The verdict
NCT00917683 was terminated before completion, sponsored by State University of New York - Upstate Medical University.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
Previously it has been shown that Familial Encephalopathy with neuroserpin inclusion bodies (FENIB) patients develop abnormalities that partially overlap with Autism Spectrum disorders (ASD), confounded with additional features that could be explained by inclusion body formation not expected in subjects with inclusion body forming SERPINI1 mutations. There is no described human neuroserpin deficiency phenotype. The neuroserpin knockout mouse phenotype also suggests a possible overlap with autism. Neuroserpin could contribute directly at the synapse or through altered neuron migration during early development leading to the "underconnectivity" that underlies autism by potentially contributing to the excess of short connections and not enough long ones seen in autistic brains, possibly due to an imbalance in pruning of neurons and synapses early in life. It is thus proposed to sequence the neuroserpin gene in initially 20, and subsequently up to 100 idiopathic autistic patients selected as having the language impairment and perseveration endophenotypes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00917683
The ClinicalTrials.gov registry entry for NCT00917683 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00917683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00917683 about?
NCT00917683 is a clinical study titled "Investigation of Neuroserpin as an Autism Candidate Gene". Previously it has been shown that Familial Encephalopathy with neuroserpin inclusion bodies (FENIB) patients develop abnormalities that partially overlap with Autism Spectrum disorders (ASD), confounded with additional features that could be explained by inclusion body formation not expected in subj...
What is the current status of trial NCT00917683?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2009-06. Estimated completion is 2012-04.
Who is sponsoring clinical trial NCT00917683?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.